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(11.9%) was found comparing to all centers data (p < 0.001 
for all). The strategy of precathlab administration of  P2Y12 
inhibitors applies to about half of STEMI patients in Poland. 
Generally, ticagrelor or prasugrel use is low, and not equally 
distributed among centers. In centers with high usage, tica-
grelor is main newer generation  P2Y12 inhibitor for precath-
lab and periprocedural administration.
Keywords Myocardial infarction · Primary PCI · 
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Introduction
Antiplatelet therapy plays a key role in the treatment of 
patients with ST-segment elevation acute myocardial infarc-
tion (STEMI) referred to primary percutaneous coronary 
intervention (PCI). According to current guidelines, prasu-
grel and ticagrelor are the first choice antiplatelet drugs in 
patients with STEMI [1]. However, practical approach to 
antiplatelet treatment is quite heterogeneous among primary-
PCI networks worldwide [2–7]. Generally, in daily clinical 
practice, the usage of those drugs as compared to clopidogrel 
is lower than expected. The timing of  P2Y12 administration 
(precathlab vs. periprocedural) is also a matter of debate due 
to lack of clear evidence from clinical trials on advantage of 
any strategy [8, 9]. Practical approach varies from network 
to network and include early prehospital but also periproce-
dural administration [10]. Moreover, the switch from and to 
clopidogrel is quite frequent both during in-hospital stay and 
follow-up [11]. Thus, we sought to analyze data on antiplate-
let treatment strategies in STEMI patients in Poland based 
on patients included in large scale Polish ORPKI national 
registry.
Abstract According to guidelines, it is recommended to 
give  P2Y12 inhibitors (preferably ticagrelor or prasugrel) at 
the time of first medical contact in patients with STEMI. 
However, in real life antiplatelet treatment strategies are dif-
ferent among countries. We analyzed data on antiplatelet 
treatment in STEMI patients included into Polish ORPKI 
national registry. A total of 23,139 STEMI patients from 
153 invasive cardiology centers were reported in ORPKI 
registry between September 2015 and August 2016. Finally 
19,437 patients from 122 centers (immediate PCI in 94%) 
were included into the analysis (lack of ticagrelor or pras-
ugrel usage reported in 31 centers). The dominant  P2Y12 
inhibitor was clopidogrel (69%) with a high rate of precath-
lab administration (51.3%). Ticagrelor was administered in 
10.1% of patients (2.3% during precathlab phase) and prasu-
grel in 1.1% (0.4% precathlab). The periprocedural switch 
from clopidogrel to newer generation oral  P2Y12 inhibitors 
was rare (to ticagrelor: 2%; to prasugrel: 0.15%). Analysis 
of data from top 10 centers with the highest rate of newer 
generation  P2Y12 inhibitors usage (1295 patients) revealed 
ticagrelor administration in 43.1% (prasugrel in 3%). During 
precathlab phase higher proportion of ticagrelor instead of 
clopidogrel (ticagrelor 17.9%, clopidogrel 29.8%) and higher 
rate of periprocedural switch from clopidogrel to ticagrelor 
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Methods
Presented analysis is based on data stored in the electronic 
database of National PCI Registry (ORPKI) operated by the 
Jagiellonian University Medical College in Krakow. ORPKI 
is a national registry collecting data on all percutaneous pro-
cedures in interventional cardiology performed in Poland 
[7]. For the study data on patients with STEMI included into 
the registry between September 2015 and August 2016 were 
analyzed. Centers using only clopidogrel (no ticagrelor, no 
prasugrel) were excluded. All procedures were carried out 
according to current medical standards. The decision to use 
 P2Y12 inhibitor (type, time, dose) was the operator’s choice 
according to clinical practice standards.
Due to relatively low penetration of newer generation oral 
 P2Y12 inhibitors in the studied cohort, we decided to per-
form additional analysis based on data from top 10 centers 
with the highest rate of ticagrelor/prasugrel usage to better 
understand the characteristics of the population treated with 
those drugs. The minimal number of patients for the center 
to be included in top 10 group was 50 per center in the above 
mentioned period.
Statistical analysis
The analysis was performed based on standard descriptive 
statistics. Quantitative variables were presented as median 
with interquartile range (IQR) and categorical variables 
as percentages. Continuous variables were expressed as 
mean ± standard deviation (SD) or median and IQR. Nor-
mality was assessed by the Shapiro–Wilk test. Equality of 
variances was assessed using the Levene’s test. Differences 
between groups were compared using the Student’s or the 
Welch’s t-test depending on the equality of variances for nor-
mally distributed variables. The Mann–Whitney U test was 
used for non-normally distributed continuous variables or 
for ordinal variables. Categorical variables were compared 
by the Fisher’s exact test for 2 × 2 tables or by Pearson’s chi-
squared test for contingency tables with higher dimensions. 
The level of statistical significance was set at p < 0.05. All 
analyses were carried out with  JMP®, Version 12.2.0 (SAS 
Institute Inc., Cary, NC, USA).
Results
Study population
A total of 23,139 STEMI patients from 153 invasive cardi-
ology centers in Poland were reported in the ORPKI regis-
try from September 2015 to August 2016. Finally, 19,437 
patients from 122 centers were included into the analysis 
(lack of ticagrelor and prasugrel usage was reported in 
remaining 31 centers). Study group represents real-life 
STEMI population (Table 1). Median time from pain onset 
to first balloon inflation was 248 (Q1–Q3: 146–540) min. 
The radial approach was selected for 72% of patients. At 
baseline, patent (TIMI grade 2/3 flow) infarct-related 
artery (IRA) was found in 27%. The left anterior descend-
ing coronary artery was identified as IRA in 41% of 
patients. Immediate PCI was performed in 93.7% with 
aspiration thrombectomy in 13% and stent implantation 
in 92.4% (95% DES). Final TIMI 3 flow grade after PCI 
was presented in 91.4%. Periprocedural anticoagulant was 
unfractionated heparin in most of the cases (including pra-
cathlab administration in 47.7%) except low molecular 
heparin in 4.4% and bivalirudin in 0.3% of patients.
Table 1  Characteristics of total study cohort
CABG coronary artery bypass graft, COPD chronic obstructive pul-
monary disease, PCI percutaneous coronary intervention, TIMI 
thrombolysis in myocardial infarction
Variable n = 19,437
Age (years) Me(Q1;Q3) 64.00 (57.00;74.00)
Gender (male) 67.7%
Diabetes mellitus 18.1%
Previous stroke 3.3%
Previous myocardial infarction 13.6%
Previous PCI 12.5%
Previous CABG 2%
Smoking 29%
Arterial hypertension 60.4%
Chronic renal disease 3.5%
COPD 2.2%
Precathlab cardiac arrest 5.5%
Killip class on admission 1 83%
2 9.5%
3 3.4%
4 4.1%
Vascular access Left radial 14.7%
Right radial 57.2%
Femoral 27.5%
Other 0.6%
Immediate PCI 93.7%
TIMI before PCI 0 59.6%
1 13.3%
2 14.0%
3 13.1%
TIMI after PCI 0 2.6%
1 1.6%
2 4.4%
3 91.4%
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Antiplatelet treatment
Total study cohort
Aspirin was given before cathlab in 72%, and during the 
procedure in 25% of patients. The dominant  P2Y12 inhibi-
tor was clopidogrel (69%) with a high rate of precathlab 
administration (51.3% of total cohort). Ticagrelor was 
administered in 10.1% of patients (2.3% during precath-
lab phase) and prasugrel in 1.1% (0.4% precathlab). The 
periprocedural switch from clopidogrel to newer genera-
tion oral  P2Y12 inhibitors was rare (to ticagrelor: 2%; to 
prasugrel: 0.15%). The distribution of clopidogrel, ticagre-
lor and prasugrel for both precathlab and periprocedural 
administration is presented in Fig. 1A. Glycoprotein IIb/
IIIa inhibitors were administered in about one-third of 
patients (mostly eptifibatide).
Analysis based on top 10 centers with the highest rate 
of ticagrelor or prasugrel usage
When analyzed data from top 10 centers with the highest rate 
of ticagrelor or prasugrel usage (1295 patients; clopidogrel 
53.9%; ticagrelor 43.1%; prasugrel 3%) we found relatively 
higher proportion of ticagrelor instead of clopidogrel dur-
ing precathlab phase (ticagrelor 17.9%, clopidogrel 29.8%; 
p < 0.001 comparing to all centers data for both) and higher 
rate of periprocedural switch from clopidogrel to ticagrelor 
(11.9%; p < 0.001 comparing to all centers data). The dis-
tribution of clopidogrel, ticagrelor, and prasugrel are pre-
sented in Fig. 1B. Patients treated with ticagrelor or prasug-
rel comparing to clopidogrel were younger, more often male 
with a lower rate of chronic obstructive pulmonary disease 
(COPD). A higher rate of TIMI 3 flow grade after PCI was 
found in ticagrelor or prasugrel patients comparing to the 
clopidogrel group (Table 2). All centers included in Top 10 
Fig. 1  The distribution of clopidogrel, ticagrelor and prasugrel for both precathlab and periprocedural administration. A Data from all centers, 
B data from top 10 centers (see text for details)
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were high volume with more than 400 PCI/year (from about 
600 to about 2500 PCI/year).
Discussion
The main findings of our study are as follows: the usage 
rate of newer generation  P2Y12 inhibitors in STEMI patients 
referred to primary PCI in Poland is still low. In addition, 
there are significant differences between networks in the 
proportion of ticagrelor/prasugrel and clopidogrel (from 
zero to almost half of patients) use. The main newer genera-
tion  P2Y12 inhibitor is ticagrelor, the rate of periprocedural 
escalate switching (from clopidogrel to ticagrelor/prasug-
rel) is up to 12% in top newer generation  P2Y12 inhibitor 
centers, the precathlab administration of  P2Y12 inhibitors is 
relatively high but heterogeneous in terms of clopidogrel to 
ticagrelor/prasugrel proportions.
According to guidelines, newer generation  P2Y12 inhibi-
tors (ticagrelor and prasugrel) are preferred over clopidogrel 
in patients with STEMI [1]. However, many reports shows 
that clopidogrel is still frequently used despite lack of con-
traindications to ticagrelor and prasugrel. In the GRAPE 
Study (data based on year 2012 registry; acute coronary 
syndromes (ACS) patients with 53% of STEMI), the initial 
choice of clopidogrel was present in about 70% of patients. 
However, at discharged this number was significantly lower 
(less than 40%) what may suggest a conservative approach 
in the acute phase (clopidogrel) following in-hospital treat-
ment escalate to newer generation oral  P2Y12 inhibitors 
[2]. Those proportions are different in recently published 
data. In the rapport from four centers from Austria (data 
from year 2015) clopidogrel was administered initially in 
29% of patients with ACS (22% of STEMI patients) and 
27% at discharge (STEMI 18.7%), confirming that major-
ity of patients were treated with newer generation  P2Y12 
Table 2  Characteristics of patients from top 10 centers with the highest rate of newer generation  P2Y12 inhibitors usage
CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, LAD left anterior coronary artery, PCI percutaneous coro-
nary intervention, TIMI thrombolysis in myocardial infarction;
Variable Prasugrel/ticagrelor (n = 597) Clopidogrel (n = 698) p
Age (years) Me(Q1;Q3) 63.00 (55.00;71.00) 66.00 (58.00;77.00) < 0.0001
Gender (male) 74.2% 66.2% 0.0017
Diabetes 16.6% 20.6% 0.06
Previous stroke 2.7% 3.7% 0.29
Previous myocardial infarction 16.8% 19.3% 0.23
Previous PCI 16.8% 19.3% 0.24
Previous CABG 1.8% 2.3% 0.57
Smoking 33.5% 33% 0.83
Arterial hypertension 72% 68.9% 0.22
Chronic renal disease 3.5% 4.4% 0.40
COPD 0.8% 2.7% 0.0122
Killip class on admission 1 87.8% 83.3% 0.19
2 6% 8.7%
3 2.4% 3.1%
4 3.8% 4.9%
Vascular access Radial left 6.1% 8% 0.007
Radial right 58% 48.3%
femoral 35.5% 43.3%
Other 0.4% 0.4%
TIMI before PCI 0 64.7% 61.4% 0.22
1 13.2% 15.2%
2 12.3% 11.1%
3 9.8% 12.3%
TIMI after PCI 0 1.2% 3.2% 0.0047
1 0.7% 1.1%
2 3% 4.8%
3 95.1% 91.9%
LAD treated during PCI 39.8% 38.1% 0.54
155Contemporary use of  P2Y12 inhibitors in patients with ST-segment elevation myocardial…
1 3
inhibitors [3]. In EYESHOT Study from Italy (data col-
lected in years 2013/2014) clopidogrel at discharge was 
prescribed in more than half of patients with ACS (32% in 
STEMI patients treated with primary PCI) [4]. In APATHY 
Registry (also data from Italy, year 2014) clopidogrel was 
administered in 52% of patients [5]. The report from the 
US based registry on ACS patients enrolled from 2011 to 
2014 have shown clopidogrel usage in 77.6%. However, the 
penetration of newer generation  P2Y12 inhibitors was higher 
in STEMI (clopidogrel usage in less than 60% of patients) 
[6]. In our report (data from years 2015/2016) the rate of 
ticagrelor and prasugrel usage was low and there were large 
differences between centers in Poland (from zero to almost 
half of STEMI patients). It should be underlined that newer 
generation  P2Y12 inhibitors are not reimbursed in Poland. 
Low prasugrel availability on Polish market may explain a 
large discrepancy between ticagrelor and prasugrel usage. 
Moreover, the reason for high usage of clopidogrel is not 
clear and the presence of contraindications may not explain 
it. In above-mentioned registry from Austria, about 55% 
of patients discharged on clopidogrel had no absolute con-
traindications to newer generation  P2Y12 inhibitors [3]. In 
GRAPE registry, the selection of clopidogrel at discharge 
was less preferred in about 75% of patients [2]. In APATHY 
Registry only 48% of patients received antiplatelet therapy 
according to guidelines [5]. Data from registries showed 
that “typical” patient for newer generation  P2Y12 inhibitors 
administration is relatively young male, undergone PCI for 
STEMI and without COPD and without a need for oral anti-
coagulation, with low bleeding risk. In our study, it was not 
possible to analyze all factors to assess current adherence 
to guidelines but we also observed that newer generation 
 P2Y12 inhibitors were more often administered to young 
male patients with a lower rate of COPD. During hospitali-
zation, the rate of switching from and to clopidogrel was 
different in different reports. In GRAPE registry one-third 
of patients initially treated with clopidogrel was switched 
to ticagrelor or prasugrel during hospitalization [2]. On 
the contrary, in EYESHOT Registry the escalate switch 
occurred only in 3.6% during the procedure and 14.2% of 
patients at discharge among patients receiving revasculari-
zation [4]. Similarly, Tscharre et al. showed a low rate of 
in-hospital switching between clopidogrel and newer genera-
tion  P2Y12 inhibitors [3]. The SCOPE Registry was focused 
on the incidence of oral  P2Y12 inhibitors switching in ACS 
patients treated with PCI and on the 30-day outcomes. About 
40% of patients were initially treated with clopidogrel. The 
switching rate was 9.6% (2.3% in cathlab, 3.3% at discharge, 
and 5.1% at follow-up). The de-escalate switching (from 
newer generation to old  P2Y12 inhibitors) in an early phase 
of ACS was an independent predictor of net adverse events 
[12]. On the other hand results of recently published TOPIC 
Trial suggests that the “late” switch to clopidogrel (after 
1 month from PCI in ACS) may reduce the rate of bleeding 
events without increasing the risk of ischemic events [13]. 
In TROPICAL-ACS Trial platelet function testing guided 
de-escalation of antiplatelet treatment was non-inferior to 
standard treatment with prasugrel at 1 year after (net clini-
cal benefit) [14]. In our study, the rate of periprocedural 
escalate switch was about 2%. However, in top centers it 
was six times higher. The reason for significant differences 
in escalate switching rate between centers is not clear. In 
some networks old approach with a high rate of prehospital 
clopidogrel administration may be the reason (despite lack 
of contraindications for ticagrelor to be administered on top 
of clopidogrel) [15]. In top 10 centers in Poland (accord-
ing to newer generation  P2Y12 inhibitors usage rate), the 
rate of prehospital clopidogrel administration was lower 
than in general cohort. This is along to concept proposed 
in 2011 by experts in Poland to postpone the decision of 
 P2Y12 inhibitor administration until cathlab hospital admis-
sion [16]. It should be underlined that when this concept was 
born, ticagrelor and prasugrel were available only in cath-
lab hospitals. Before introducing of newer generation oral 
 P2Y12 inhibitors, clopidogrel was available and widely used 
in many networks in ambulance [17]. Currently, ticagrelor 
is also available in growing number of ambulances based on 
new regulations. So in top 10 centers we observed less clopi-
dogrel administered early and more ticagrelor administered 
both early as well as during procedure. Also, the peripro-
cedural escalate switching in those centers was about 12% 
showing that antiplatelet treatment strategy was reassessed 
during the procedure. Data on the effectiveness of the strat-
egy of early (prehospital)  P2Y12 inhibitors administration 
in STEMI patients is not clear. ATLANTIC trial has shown 
no clear benefit of early ticagrelor administration but the 
time from loading dose administration to the procedure was 
relatively short [8]. On the other hand, in many European 
centers such approach is a part of daily practice in STEMI 
treatment showing some clinical benefit [9]. All those data 
on type, time of administration and eventual switch between 
 P2Y12 suggest the need for tailored rather than systematic 
approach, what will be the future challenge in the treatment 
of patients with ACS.
Limitations
The main limitation of presented analysis is lack of data 
on discharge and follow-up antiplatelet treatment as well 
as in-hospital and follow-up adverse events rate. Only 
periprocedural events rate was available and we decide not 
to include it into presented analysis because we wanted to 
analyze treatment patterns but not impact of selected  P2Y12 
inhibitors on outcomes. We were not able to fully analyze 
adherence to guidelines due to lack of full data concerning 
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contraindications to a particular  P2Y12 inhibitor. The 
analysis is based on national registry data not individually 
monitored.
Conclusions
Clopidogrel remains the most common  P2Y12 inhibitor 
administered in STEMI patients referred to primary PCI in 
Poland. The penetration of newer generation  P2Y12 inhibi-
tors is low, and there are significant differences between 
networks in the proportion of ticagrelor/prasugrel and clopi-
dogrel usage. These suggest the need for a greater effort to 
improve adherence to guidelines regarding oral antiplatelet 
treatment in STEMI.
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